Peanut Protein and Increased Peanut Protein Eliciting Dose

Doses used in studies

Time to effect

Median: 12.2 months · IQR 12.2 months–12.2 months · Range 12.2 months–12.2 months — Reported in 1 of 1 study

Safety in these studies

serious adverse eventsNo significant differenceSerious adverse event
No dose-related serious AEs were observed.
from: Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Pro
dropout for treatment-related adverse eventsReported0.9%
The overall median adherence was 97.6% after 1 year; the dropout rate for treatment-related AEs was 0.9%.
from: Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Pro
treatment-emergent adverse eventsReported
The percentage of patients with 1 or more TEAEs (largely local skin reactions) was similar across all groups in year 1: 50-μg patch = 100%, 100-μg patch = 98.2%, 250-μg patch = 100%, and placebo patch = 92.9%.
from: Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Pro

1 of 1 paper

Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity: A Randomized Clinical Trial.